Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alison Fleig

Physician Assistant Toledo, OH Physician Assistant

NPI 1013312693 CMS profile 10689095

3830 Woodley Rd Ste 2A, Toledo, OH 43606

Open in the dashboard

General payments

$47,829

588 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alison Fleig of Toledo, OH is reported in the CMS Open Payments database as having received $47,829 across 588 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,138 106
2024 General $8,229 107
2023 General $7,457 130
2022 General $10,087 139
2021 General $13,919 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alison Fleig
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alison Fleig were reported at $8,138. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alison Fleig Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $13,919 $132 $37–$438 $132
2022 $10,087 $155 $48–$522 $149
2023 $7,457 $167 $52–$557 $160
2024 $8,229 $178 $55–$600 $164
2025 $8,138 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Insulet Corporation $20,367 82 payments
  2. Medtronic, Inc. $15,563 40 payments
  3. Tandem Diabetes Care, Inc. $6,061 48 payments
  4. Novo Nordisk Inc $1,095 121 payments
  5. Lilly USA, LLC $709 47 payments
  6. Dexcom, Inc. $554 62 payments
  7. Amgen Inc. $375 23 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $352 19 payments
  9. Corcept Therapeutics $348 12 payments
  10. Antares Pharma, Inc. $272 15 payments
  11. Other $2,135 119 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,006 95 payments
  2. Food and Beverage $6,583 482 payments
  3. Gift $240 11 payments
Products named General payments · program years 2021–2025
  1. Omnipod $20,367 82 payments
  2. MINIMED 780G $9,485 27 payments
  3. t:slim X2 Insulin Pump with Control-IQ $6,061 48 payments
  4. Minimed 770G System $3,925 3 payments
  5. MINIMED 770G $2,123 7 payments
  6. Ozempic $1,038 118 payments
  7. RYBELSUS $956 113 payments
  8. Dexcom G6 Transmitter $393 42 payments
  9. JARDIANCE $370 22 payments
  10. Korlym $348 12 payments
  11. Other $4,203 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

3,562

Median for Physician Assistant: 241

Drug cost

$1,671,736

Median for Physician Assistant: $4,110

Branded share of claims

59.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 253 $320,473
Mounjaro Tirzepatide Brand 132 $174,845
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 54 $144,010
Trulicity Dulaglutide Brand 97 $127,806
Tresiba Flextouch U-200 Insulin Degludec Brand 41 $85,293
Jardiance Empagliflozin Brand 104 $81,669
Humalog Kwikpen U-200 Insulin Lispro Brand 15 $62,065
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 67 $61,622
Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt Brand 42 $59,727
Tresiba Flextouch U-100 Insulin Degludec Brand 78 $49,268

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$18,038

Medicare's payments for the services billed

Medicare patients

106

Average age 70

Services billed

451

55 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 61%
Arthritis 60%
Ischemic heart disease 44%
Depression 42%
Heart failure 32%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $132
  • Lilly USA, LLC $117
$249 104 —
XYOSTED
  • Antares Pharma, Inc. $109
$109 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $96
$96 — —
Korlym
  • Corcept Therapeutics $75
$75 — —
RYBELSUS
  • Novo Nordisk Inc $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

588 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record